Five-year prognostic impact of pre-existing interstitial lung disease in non-small cell lung cancer patients treated with anti-PD-1 monotherapy: a retrospective analysis.
1/5 보강
OpenAlex 토픽 ·
Cancer Immunotherapy and Biomarkers
Lung Cancer Diagnosis and Treatment
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
APA
Teppei Yamaguchi, Junichi Shimizu, et al. (2026). Five-year prognostic impact of pre-existing interstitial lung disease in non-small cell lung cancer patients treated with anti-PD-1 monotherapy: a retrospective analysis.. BMC cancer. https://doi.org/10.1186/s12885-026-15989-1
MLA
Teppei Yamaguchi, et al.. "Five-year prognostic impact of pre-existing interstitial lung disease in non-small cell lung cancer patients treated with anti-PD-1 monotherapy: a retrospective analysis.." BMC cancer, 2026.
PMID
42035031 ↗
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Correction to "Systemic microRNA Delivery Using Polysaccharide-Coated Nanobubbles for Ultrasound-Mediated Therapy of Triple-Negative Breast Cancer".
- Clinical Outcomes and Prognostic Factors After Total Pancreatectomy: A Single-center Retrospective Study of 43 Cases.
- [A Case of Sigmoid Colon Cancer with Synchronous Pulmonary Metastases Diagnosed during Follow-Up after Primary Tumor Resection].
- HIFU induces reprogramming of the tumor immune microenvironment in a pancreatic cancer mouse model.
- Asthma is a risk factor for postoperative pulmonary complications and intra-abdominal infectious complications after gastrectomy.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- SLC2A1 tumour-associated macrophages spatially control CD8 T cell function and drive resistance to immunotherapy in non-small-cell lung cancer.
- Distribution of Immune Cells in Tumor Microenvironment Correlates With Checkpoint Inhibitor Response in Nasopharyngeal Carcinoma: A Multiregional Study.
- Immune Checkpoint Inhibitors for Recurrent Hepatocellular Carcinoma After Liver Transplantation: Safety Under an Immunosuppression-Preserving Strategy.
- Enhanced efficacy and long-term survival with SBRT plus PD-1 inhibitors versus SBRT alone in unresectable HCC: a multicenter PSM study.
- TIM-3 inhibition enhances breast tumor progression and metastasis: A paradoxical immune checkpoint response.
- Association of immune-related adverse events with survival in patients receiving immune checkpoint inhibitor plus chemotherapy for lung cancer.